

Yong Su

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6648962/publications.pdf>

Version: 2024-02-01

15
papers

192
citations

1307594

7
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

265
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical target volume design of postoperative intensity-modulated radiotherapy for major salivary gland tumours according to surgical principles: an innovative method. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 921-930.	2.5	0
2	Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1931-1942.	2.5	6
3	Failure patterns and prognostic factors for cervical node-negative nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 330-337.	1.1	1
4	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up. <i>Radiation Oncology</i> , 2021, 16, 215.	2.7	7
5	Late-course accelerated hyperfractionated intensity-modulated radiotherapy for nasopharyngeal adenoid cystic carcinoma: A case report. <i>Medical Dosimetry</i> , 2020, 45, 46-51.	0.9	1
6	Is Surgery an Inevitable Treatment for Advanced Salivary Lymphoepithelial Carcinoma? Three Case Reports. <i>Ear, Nose and Throat Journal</i> , 2020, 100, 014556132092317.	0.8	8
7	Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis. <i>Radiation Oncology</i> , 2020, 15, 160.	2.7	4
8	Target delineation and dose prescription of adaptive replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2019, 39, 1-4.	9.2	8
9	Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 685-695.	3.0	27
10	Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 76.	2.4	12
11	Using CT or MRI to assess locoregional spread to determine the radiotherapy target of hypopharyngeal carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, e21-7.	1.1	2
12	Prognostic value of tumor volume for patients with nasopharyngeal carcinoma treated with concurrent chemotherapy and intensity-modulated radiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 69-76.	2.5	46
13	Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. <i>Head and Neck</i> , 2013, 35, 689-694.	2.0	42
14	Analysis of risk factors for retropharyngeal lymph node metastasis in carcinoma of the hypopharynx. <i>Head and Neck</i> , 2013, 35, 1274-1277.	2.0	20
15	Analysis of cervical and retropharyngeal lymph node metastases in the patients with hypopharyngeal carcinoma with computed tomography and magnetic resonance imaging. <i>Chinese Journal of Cancer</i> , 2010, 29, 189-193.	4.9	8